Grifols (Grifols) Change In Receivables

: $0 Mil (TTM As of Sep. 2023)

View and export this data going back to 2011. Start your Free Trial

Grifols's change in receivables for the quarter that ended in Sep. 2023 was $0 Mil. It means Grifols's Accounts Receivable stayed the same from Jun. 2023 to Sep. 2023 .

Grifols's change in receivables for the fiscal year that ended in Dec. 2023 was $-58 Mil. It means Grifols's Accounts Receivable increased by $58 Mil from Dec. 2022 to Dec. 2023 .

Grifols's Accounts Receivable for the quarter that ended in Sep. 2023 was $925 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Grifols's Days Sales Outstanding for the three months ended in Sep. 2023 was 49.51.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Grifols's liquidation value for the three months ended in Sep. 2023 was $-11,269 Mil.

Grifols Change In Receivables Historical Data

The historical data trend for Grifols's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-110.42

-43.10

-18.99

-84.93

-57.95

Grifols Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Change In Receivables																-	-	-	-	-

Grifols Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Grifols (NAS:GRFS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Grifols's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	925.003	/	1704.89	*	91
=	49.51

2. In Ben Graham's calculation of liquidation value, Grifols's accounts receivable are only considered to be worth 75% of book value:

Grifols's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	580.188	-	14403.21	+	0.75 * 925.003	+	0.5 * 3721.113
=	-11,269

Grifols Change In Receivables Related Terms

Thank you for viewing the detailed overview of Grifols's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0F0:Germany G0F:Germany G0FB:Germany OZTA:Germany OZTA:Germany G0FB:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.